全球知名制药公司诺和诺德盘前大涨5.33%,引发市场广泛关注。
分析人士认为,尽管近期公司旗舰产品Ozempic和Wegovy的销售低于预期,且这两款产品被Medicare列入2027年药价谈判名单引发担忧,但长期来看诺和诺德前景可期。
一方面,Ozempic和Wegovy针对肥胖症和糖尿病仍有强劲市场需求。另一方面,诺和诺德正在开发包括CagriSema和口服版司美格鲁肽等多个潜力巨大的新药,有望进一步拓展公司业务。鉴于此,华尔街分析师普遍看好该公司长期增长前景,其平均12个月目标价比当前股价高出39%左右。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.